Cáncer de Pulmón Revisión sobre los Alcances e Innovaciones en Clasificación, Manejo y Terapéutica
Resumen
Se proporciona una revisión exhaustiva sobre el cáncer de pulmón, abarcando desde su incidencia y clasificación hasta las innovaciones recientes en su manejo y tratamiento. El cáncer de pulmón es la neoplasia más común a nivel mundial, siendo el tercer tipo de cáncer más frecuente después del de mama y próstata. A pesar de una leve disminución en su incidencia general estandarizada por edad en los últimos 40 años, aún representa la mayor proporción de muertes relacionadas con cáncer. La revisión destaca la importancia de una estadificación precisa para determinar el tratamiento y pronóstico adecuados, señalando el avance en técnicas de imagen como la tomografía por emisión de positrones con tomografía computarizada (PET-CT) y el ultrasonido endobronquial (EBUS) para una mejor precisión en la estadificación. Se detalla la octava edición del sistema de clasificación TNM por sus siglas en inglés (Tumor, Nodo, Metástasis), utilizada desde enero de 2017, que proviene de la base de datos de la Asociación Internacional para el Estudio del Cáncer de Pulmón (IASLC).
Descargas
Citas
International Agency for Research on Cancer . Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide 2012 . http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
Cancer research UK . Lung cancer statistics www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer.
Royal College of Physicians . The National Lung Cancer Audit report 2016 . London : RCP , 2016 .
Walters S , Benitez-Majano S , Muller P et al. Is England closing the international gap in cancer survival? Br J Cancer 2015 ; 113 : 848 – 60 .
Goldstraw P , Chansky K , Crowley J et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer . J Thorac Oncol ; 11 : 39 – 51 .
De Ruysscher D , Wanders R , van Baardwijk A et al. Radical treatment of non–small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450) . J Thorac Oncol 2012 ; 7 : 1547 – 55 .
Tanvetyanon T , Robinson LA , Schell MJ et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis . J Clin Oncol 2008 ; 26 : 1142 – 7 .
Moreno P , de la Quintana Basarrate A , Musholt TJ et al. Adrenalectomy for solid tumor metastases: results of a multicenter European study . Surgery 2013 ; 154 : 1215 – 22 ; discussion 1222-3 .
Office for National Statistics . Cancer survival by stage at diagnosis for England (experimental statistics): Adults diagnosed 2012, 2013 and 2014 and followed up to 2015 . ONS , 2016 .
Falcoz PE , Puyraveau M , Thomas PA et al. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-smallcell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database . Eur J Cardiothorac Surg 2016 ; 49 : 602 – 9 .
Whitson BA , Groth SS , Duval SJ , Swanson SJ , Maddaus MA . Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy
approaches to lobectomy . Ann Thorac Surg 2008 ; 86 : 2008 – 16 ; discussion 16–8 .
Riaz SP , Linklater KM , Page R et al. Recent trends in resection rates among non-small cell lung cancer patients in England . Thorax 2012 ; 67 : 811 – 14 .
Powell HA , Tata LJ , Baldwin DR et al. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit . Thorax 2013 ; 68 : 826 – 34.
Rich AL , Tata LJ , Free CM et al. Inequalities in outcomes for nonsmall cell lung cancer: the influence of clinical characteristics and features of the local lung cancer service . Thorax 2011 ; 66 : 1078 – 84 .
Khakwani A , Rich AL , Powell HA et al. The impact of the ‘hub and spoke’ model of care for lung cancer and equitable access to surgery . Thorax 2015 ; 70 : 146 – 51 .
Grutters JP , Kessels AG , Pijls-Johannesma M et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis . Radiother Oncol 2010 ; 95 : 32 – 40 .
Timmerman R , Paulus R , Galvin J et al. Stereotactic body radiation therapy for inoperable early stage lung cancer . JAMA 2010 ; 303 : 1070 – 6 .
Lagerwaard FJ , Senan S , van Meerbeeck JP et al. Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer? Radiother Oncol 2002 ; 63 : 151 – 7 .
Verstegen NE , Oosterhuis JW , Palma DA et al. Stage I-II nonsmall-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis . Ann Oncol 2013 ; 24 : 1543 – 8 .
Paul S , Lee PC , Mao J , Isaacs AJ , Sedrakyan A . Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis . BMJ 2016 ; 354 : i3570.
Dupuy DE , Zagoria RJ , Akerley W et al. Percutaneous radiofrequency ablation of malignancies in the lung . AJR Am J Roentgenol 2000 ; 174 : 57 – 9.
Bargellini I , Bozzi E , Cioni R , Parentini B , Bartolozzi C . Radiofrequency ablation of lung tumours . Insights into Imaging 2011 ; 2 : 567 – 76 .
Pintos, M. M. (2022). La responsabilidad social de los abogados. Estudios Y Perspectivas Revista Científica Y Académica , 2(2), 92–114. https://doi.org/10.61384/r.c.a.v2i2.23
Acosta Silva, S., & Paredes Cruz, I. (2022). Prevención y tratamiento de la litiasis renal: Medidas dietéticas y farmacológicas. Revista Científica De Salud Y Desarrollo Humano, 3(1), 148–170. https://doi.org/10.61368/r.s.d.h.v3i1.50
González, L. (2023). Evaluación de la Conexión entre la Administración Educativa Participativa y la Excelencia en la Enseñanza en Instituciones Públicas de América Latina. Emergentes - Revista Científica, 3(1), 132–150. https://doi.org/10.60112/erc.v3i1.25
Chavarría Oviedo, F., & Avalos Charpentier, K. (2022). Material Designing for English Language Learners With ASD, Visual Impairments and Muteness. Sapiencia Revista Científica Y Académica , 2(2), 71–91. Recuperado a partir de https://revistasapiencia.org/index.php/Sapiencia/article/view/23
European Commission. (2023). Ethical Guidelines on the Use of Artificial Intelligence (AI) and Data in Teaching and Learning for Educators. Available online: https://op.europa.eu/en/publication-detail/-/publication/d81a0d54-5348-11ed-92ed-01aa75ed71a1/language-en (accessed on 18 November 2023)
Lencioni R , Crocetti L , Cioni R et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study) . Lancet Oncol 2008 ; 9 : 621 – 8 .
Scagliotti GV , Parikh P , von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer . J Clin Oncol 2008 ; 26 : 3543 – 51 .
Kris MG , Natale RB , Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: A randomized trial . JAMA 2003 ; 290 : 2149 – 58.
Lynch TJ , Bell DW , Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib . N Engl J Med 2004 ; 350 : 2129 – 39 .
Maemondo M , Inoue A , Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR . N Engl J Med 2010 ; 362 : 2380 – 88 .
Herbst RS , Baas P , Kim DW . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial . Lancet 2016 ; 387 : 1540 – 50 .
Borghaei H , Paz-Ares L , Horn L et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer . N Engl J Med 2015 ; 373 : 1627 – 39 .
Antonia SJ , López-Martin JA , Bendell J et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial . Lancet Oncol 2016 ; 17 : 883 – 95 .
Temel JS , Greer JA , Muzikansky A et al. Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer . N Engl J Med 2010 ; 363 : 733 – 42 .
Bakitas MA , Tosteson TD , Li Z et al. Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial . J Clin Oncol 2015 ; 33 : 1438 – 45 .
Ferrell BR , Temel JS , Temin S et al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update . J Clin Oncol 2017 ; 35 : 96 – 112 .
National Lung Screening Trial Research Team , Aberle DR , Adams AM et al. Reduced lung-cancer mortality with low-dose computed tomographic screening . N Engl J Med 2011 ; 365 : 395 – 409
Field JK , Duffy SW , Baldwin DR et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening . Thorax 2016 ; 71 : 161 – 70 .
Derechos de autor 2024 Juan Sebastián Theran León , Carlos Enrique Arenas Molina, Daniela Garzón Monsalve, Martin Vergara Garcia, Laura Isabel Pabón Pérez, Francisco Luis Acuña Polo , Juan Nicolas Layton , Daniel Mutis
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.jpg)
